The use of thiopurine (azathioprine and mercaptopurine) reduces the immune response to viruses, which is associated with an increased risk of opportunistic infections. There is limited evidence that they increase the risk of respiratory infections.
The risks and benefits should be considered, but most patients can continue on a stable dose. In patients in stable remission, elderly patients and in the presence of concomitant pathology, it is recommended to stop taking thiopurine.
During a pandemic, it is recommended to avoid starting thiopurine or increasing the dose, which will allow patients to avoid potential side effects.
If the patient is in contact with a COVID-19 person, temporary withdrawal of thiopurine for 2 weeks should be considered.
If a patient tests positive for SARS-CoV-2 and/or develops COVID-19, temporary discontinuation of thiopurine may be recommended until the patient clears the infection.
Thus, hypertension has been and remains a very important medical and social problem that requires appropriate attention not only from healthcare institutions and medical workers, but also from the leadership of the Ministry of Health and the state. Only through the joint efforts of representatives of medical science, health care and the entire public society can it be possible to achieve an increase in the effectiveness of the fight against this disease
Лечение кортикостероидами (особенно преднизолоном в дозе ≥20 мг/сут или его эквивалент) связано с повышенным риском инфицирования. Однако неясно, связана ли терапия кортикостероидами с повышенным риском развития COVID-19 или ее осложнений. Данные о будесониде , кортикостероидах местного действия с низкой системной биодоступностью показывают, что эти препараты связаны со значительно меньшим количеством побочных эффектов по сравнению с системными кортикостероидами и их побочные эффекты приближены к плацебо.
